Growth, clinical and neurodevelopmental outcomes at school age are similar for children who received 1-year lamivudine or lopinavir/ritonavir HIV prophylaxis in early life.
Growth, clinical and neurodevelopmental outcomes at school age are similar for children who received 1-year lamivudine or lopinavir/ritonavir HIV prophylaxis in early life.
复制标题
对于早期生活中接受1年兰米夫定或洛匹那韦/利托纳维尔HIV的1年儿童而言，学龄前年龄的增长，临床和神经发育结果相似。
DOI：
10.1038/s41598-021-82762-8
复制
发表时间：
2021-02-04
影响因子：
4.6
通讯作者：
Molès JP
中科院分区：
文献类型：
--
作者：
Nagot N;Singata-Madliki M;Cournil A;Nalugya J;Tassembedo S;Quillet C;Tonga MW;Tumwine J;Meda N;Kankasa C;Mwiya M;Bangirana P;Peries M;Batting J;Engebretsen IMS;Tylleskär T;Perre PV;Ndeezi G;Molès JP
在 ANRS 12174 试验中，与接受拉米夫定 (3TC) 治疗的新生儿相比，接受洛匹那韦-利托那韦 (LPV/r) 预防治疗 1 年的 HIV 暴露未感染非洲新生儿从出生到 50 周的生长速度较慢。我们评估了这种生长差异是否会随着时间的推移持续存在，并伴有神经心理学和临床结果的差异。 2017 年 2 月至 2018 年 2 月期间，我们对完成 50 周随访且未感染 HIV 的前试验参与者进行了横断面临床评估。除了临床检查之外，还使用 Kaufman-ABCII 测试、注意力变量测试、儿童运动评估电池以及家长版本的优势和困难问卷来评估神经心理学结果。在 1101 名 5-7 岁的符合条件的儿童中，有 553 名可被追踪和分析（LPV/r 组中 274 名，3TC 组中 279 名）。治疗组之间的生长、临床和神经心理学结果没有差异。在学龄期，出生时接触 LPV/r 和 3TC 1 年的儿童具有相似的生长和神经心理学结果，没有证据表明 LPV/r 存在长期副作用。它为所有在生命早期接受这种抗逆转录病毒药物治疗的艾滋病毒感染儿童的临床结果提供了令人放心的数据。
In the ANRS 12174 trial, HIV-exposed uninfected African neonates who received lopinavir-ritonavir (LPV/r) prophylaxis for 1 year exhibited slower growth from birth to week 50 compared with those receiving lamivudine (3TC). We assessed whether this difference in growth persisted over time, and was accompanied by differences in neuropsychological and clinical outcomes. Between February 2017 and February 2018, we conducted a cross-sectional clinical evaluation among former trial participants who completed the 50-week follow-up and who were not HIV-infected. In addition to clinical examination, neuropsychological outcomes were assessed using the tests Kaufman-ABCII, Test of Variables of Attention, Movement Assessment Battery for Children and the Strengths and Difficulties questionnaire, parent version. Of 1101 eligible children, aged 5–7 years, 553 could be traced and analysed (274 in the LPV/r and 279 in the 3TC groups). Growth, clinical and neuropsychological outcomes did not differ between treatment groups. At school age, children exposed to LPV/r and 3TC at birth for 1 year had comparable growth and neuropsychological outcomes without evidence of long-term side-effects of LPV/r. It provides reassuring data on clinical outcomes for all HIV-infected children treated with this antiretroviral drug in early life.
登录
查看更多内容
使用Kaufman评估电池对与HIV相关的认知障碍进行跨文化评估：系统评价。
影响因子：
6
作者：
van Wyhe KS;van de Water T;Boivin MJ;Cotton MF;Thomas KG
通讯作者：
Thomas KG
DOI：
10.1097/qad.0000000000001683
发表时间：
2018-01-14
期刊：
AIDS (London, England)
影响因子：
--
作者：
Boivin MJ;Barlow-Mosha L;Chernoff MC;Laughton B;Zimmer B;Joyce C;Bwakura-Dangarembizi M;Ratswana M;Abrahams N;Fairlie L;Gous H;Kamthunzi P;McCarthy K;Familiar-Lopez I;Jean-Phillippe P;Coetzee J;Violari A;Cotton MF;Palumbo PE;IMPAACT P1104s Study Team
通讯作者：
IMPAACT P1104s Study Team
影响因子：
0.3
作者：
Chernoff MC;Laughton B;Ratswana M;Familiar I;Fairlie L;Vhembo T;Kamthunzi P;Kabugho E;Joyce C;Zimmer B;Ariansen JL;Jean-Philippe P;Boivin MJ
通讯作者：
Boivin MJ
DOI：
10.1111/j.2517-6161.1995.tb02031.x
发表时间：
1995-01-01
影响因子：
5.8
作者：
BENJAMINI, Y;HOCHBERG, Y
通讯作者：
HOCHBERG, Y
影响因子：
3.8
作者：
Chaudhury, Sumona;Mayondi, Gloria K.;Kammerer, Betsy
通讯作者：
Kammerer, Betsy